Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders. Established with a commitment to scientific excellence and leadership in CNS research, Acadia's proprietary drug discovery platform has enabled the creation of a robust portfolio targeting conditions such as Parkinson's disease psychosis, Alzheimer's disease psychosis, Rett syndrome, and schizophrenia.
Acadia's pivotal achievements include the development and commercialization of NUPLAZID, the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE, the first and only FDA-approved drug for the treatment of Rett syndrome. The company's clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.
Situated in San Diego, one of the largest biotechnology hubs in the United States, Acadia benefits from proximity to over 400 companies and renowned research institutions like the Salk Institute for Biological Studies. This strategic location supports Acadia's mission to bring groundbreaking therapies to patients in need.
Financially, Acadia has shown significant growth, with total revenues reaching $205.8 million for the first quarter of 2024, reflecting a 74% year-over-year increase, largely due to the strong market performance of NUPLAZID and the addition of DAYBUE. The company continues to invest in its pipeline and commercial operations, maintaining a solid cash position with $470.5 million in cash, cash equivalents, and investment securities as of March 31, 2024.
Recent highlights include participation in major healthcare conferences, strategic appointments to enhance leadership in research and development, and ongoing efforts to expand the reach of DAYBUE beyond the U.S. market. Acadia’s unwavering dedication to advancing neuroscience and improving patient outcomes underscores its long-term growth potential and commitment to innovation in the biopharmaceutical landscape.
Acadia Pharmaceuticals has launched MoreThanMemoryLoss.com, an educational website aimed at assisting caregivers and individuals living with dementia. The site offers resources about dementia-related hallucinations and delusions, a common challenge for about 30% of the 8 million people with dementia in the U.S. The initiative was developed with input from caregivers and advocacy groups, featuring guides and personal stories to encourage discussions between caregivers and healthcare providers. This resource aims to address the distressing symptoms of dementia-related psychosis.
Acadia Pharmaceuticals (Nasdaq: ACAD) will participate in two upcoming investor conferences. The 10th Annual SVB Leerink Global Healthcare Conference features a fireside chat on February 26, 2021, at 10:40 a.m. ET. The Cowen 41st Annual Health Care Conference follows with a presentation on March 1, 2021, at 12:20 p.m. ET. Both events will be held virtually, and live webcasts will be available on Acadia's website, followed by archived recordings for about one month. Acadia specializes in neuroscience breakthroughs for conditions like Parkinson’s disease psychosis.
Acadia Pharmaceuticals (Nasdaq: ACAD) will report its fourth quarter and full year 2020 financial results on February 24, 2021, after market close. A conference call to discuss these results will occur the same day at 4:30 p.m. ET, accessible via phone or webcast. Acadia is known for developing the first approved therapy for hallucinations associated with Parkinson’s disease psychosis and is focused on late-stage development for dementia-related psychosis and other CNS disorders. Future projections may be subject to risks inherent in drug development.
Acadia Pharmaceuticals (Nasdaq: ACAD) announced the departure of Michael Yang, Executive VP and Chief Commercial Officer, effective January 29, 2021, as he transitions to a CEO role at another healthcare company. Charmaine Lykins and Amanda Morgan will co-lead the commercial organization post-departure. Lykins has extensive experience in marketing and product launches in CNS disorders, while Morgan brings a strong track record in team development and sales strategies within the healthcare sector.
Acadia Pharmaceuticals (Nasdaq: ACAD) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 2:00 PM ET. The event will occur virtually, featuring a question and answer session following the presentation. A live audio webcast will be available on Acadia's website, with an archived recording accessible until February 12, 2021. Acadia is a leader in neuroscience, known for developing the first approved therapy for hallucinations and delusions related to Parkinson’s disease psychosis.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 3:20 p.m. ET. The event will be held virtually, and a live webcast of the presentation can be accessed on Acadia's website, with an archived recording available until December 15, 2020. Acadia specializes in neuroscience, having developed the first therapy for hallucinations and delusions related to Parkinson’s disease psychosis, and is involved in various research areas including dementia-related psychosis and schizophrenia.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) reported strong Q3 2020 financial results, with net sales of NUPLAZID reaching $120.6 million, marking a 27% increase year-over-year. The company anticipates a PDUFA date of April 3, 2021, for its supplemental NDA targeting dementia-related psychosis. Despite growth, Acadia posted a net loss of $84.7 million for the quarter, attributed to increased expenses related to the acquisition of CerSci Therapeutics. Cash reserves stood at $644.4 million. Guidance for NUPLAZID sales remains at $430 to $450 million for 2020.
Acadia Pharmaceuticals (Nasdaq: ACAD) will present new analyses of pimavanserin clinical data for dementia-related psychosis at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD) from November 4-7, 2020. Presentations will cover the impact of pimavanserin on cognition and motor function in neurodegenerative conditions, alongside safety assessments. Notable presentations include findings from the Phase 3 HARMONY Study and a literature review on antipsychotic treatments for dementia-related psychosis. The FDA accepted Acadia's supplemental application for pimavanserin in this indication, with a PDUFA date set for April 3, 2021.
Acadia Pharmaceuticals (ACAD) plans to report its third-quarter financial results on November 4, 2020, after market close. A conference call will follow at 4:30 PM ET to discuss the results. Participants can access the call via various numbers provided for U.S. and international callers. The call will also be available as a live webcast on Acadia's website, which will remain archived until December 2, 2020. Acadia focuses on neuroscience breakthroughs, notably the only approved therapy for Parkinson's disease psychosis, and is exploring treatments for other neuropsychiatric conditions.
Acadia Pharmaceuticals and the Lewy Body Dementia Association have announced a partnership to produce an educational adaptation of the film Robin's Wish. This new version, titled SPARK - Robin Williams and his Battle with Lewy Body Dementia, aims to increase awareness and educate healthcare professionals about Lewy body dementia (LBD), which affects 1.4 million people in the U.S. The film will be available in late October for academic institutions to aid in outreach and education on LBD symptoms and management.
FAQ
What is the current stock price of Acadia Pharmaceuticals (ACAD)?
What is the market cap of Acadia Pharmaceuticals (ACAD)?
What does Acadia Pharmaceuticals Inc. specialize in?
Where is Acadia Pharmaceuticals headquartered?
What are some of Acadia's key products?
What recent financial performance did Acadia report?
What are Acadia's current research focuses?
What recent achievements has Acadia Pharmaceuticals announced?
How does Acadia support the Rett syndrome community?
What is the significance of Acadia's location in San Diego?
How has Acadia's product portfolio grown recently?
What is Acadia’s approach to drug discovery?
